Global analysis of DNA methylation changes during progression of oral cancer

Oral Oncology

Volumn 49, Issue 11, 2013, Pages 1033-1042

  Towle, Rebecca ^a   Truong, Danielle ^b   Hogg, Kirsten ^b,c   Robinson, Wendy P ^b,c   Poh, Catherine F ^a,b   Garnis, Cathie ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dysplasia; Epigenetics; Field effect; Methylation; Oral cancer; Progression

Indexed keywords

CASPASE 8; COMPLEMENT COMPONENT C1Q; HEPATOCYTE NUCLEAR FACTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; SECRETED FRIZZLED RELATED PROTEIN 4; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR RUNX1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HUMAN; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; WNT SIGNALING PATHWAY;

CARCINOMA IN SITU; CIS; DYSPLASIA; EPIGENETICS; FIELD EFFECT; FLUORESCENCE VISUALIZATION; FV; METHYLATION; OPL; ORAL CANCER; ORAL PREMALIGNANT LESION; ORAL SQUAMOUS CELL CARCINOMA; OSCC; PROGRESSION;

ADULT; AGED; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENOMICS; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MOUTH NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84888645072     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.08.005     Document Type: Article

References (54)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108. Epub 2005/03/12.
2. Sankaranarayanan R, Sauvaget C, Ramadas K, Ngoma T, Teguete I, Muwonge R, et al. Clinical trials of cancer screening in the developing world and their impact on cancer healthcare. Ann Oncol 2011;22(Suppl 7):vii20-8. Epub 2011/ 11/09.
3. Garnis C, Buys T, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol Cancer 2004;3(9):1-23.
4. Banerjee AG, Bhattacharyya I, Vishwanatha JK. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia. Mol Cancer Ther 2005;4(6):865-75. Epub 2005/06/16.
5. Sumino J, Uzawa N, Okada N, Miyaguchi K, Mogushi K, Takahashi K, et al. Gene expression changes in initiation and progression of oral squamous cell carcinomas revealed by laser microdissection and oligonucleotide microarray analysis. Int J Cancer 2013;132(3):540-8. Epub 2012/06/29.
6. Garnis C, Chari R, Buys TP, Zhang L, Ng RT, Rosin MP, et al. Genomic imbalances in precancerous tissues signal oral cancer risk. Mol Cancer 2009;8:50. Epub 2009/07/25.
7. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 1996;30:441-64. Epub 1996/01/01.
8. Towle R, Garnis C. Methylation-mediated molecular dysregulation in clinical oral malignancy. J Oncol 2012;2012:170172. Epub 2012/05/31.
9. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC, et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 2002;62(18):5295-300. Epub 2002/09/18.
10. Cao J, Zhou J, Gao Y, Gu L, Meng H, Liu H, et al. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin Cancer Res 2009;15(16):5178-83. Epub 2009/ 08/13.
11. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 2002;62(7):2072-6. Epub 2002/04/04.
12. Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, et al. Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral Oncol 2008;44(11):1052-8. Epub 2008/05/20.
13. Bibikova M, Fan JB. Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med 2010;2(2):210-23. Epub 2010/09/14.
14. Poage GM, Butler RA, Houseman EA, McClean MD, Nelson HH, Christensen BC, et al. Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer. Cancer Res 2012;72(11):2728-37. Epub 2012/04/18.
15. Zhang S, Feng X, Shi L, Gong C, He Z, Wu H, et al. Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma. Oncol Rep 2013.
16. Jithesh P, Risk J, Schache A, Dhanda J, Lane B, Liloglou T, et al. The epigenetic landscape of oral squamous cell carcinoma. British J Cancer 2013.
17. Lane P.M, Gilhuly T, Whitehead P, Zeng H, Poh CF, Ng S, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt 2006;11(2):024006. Epub 2006/05/06.
18. Poh CF, Ng SP, Williams P.M, Zhang L, Laronde DM, Lane P, et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck 2007;29(1):71-6. Epub 2006/09/20.
19. Poh CF, Zhang L, Anderson DW, Durham JS, Williams P.M, Priddy RW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006;12(22):6716-22. Epub 2006/11/24.
20. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18(1):207-8.
21. Kanai Y, Genome-wide DNA. Methylation profiles in precancerous conditions and cancers. Cancer Sci 2010;101(1):36-45. Epub 2009/11/07.
22. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 2003;190(2):125-33. Epub 2003/02/05.
23. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7(1):21-33. Epub 2005/12/22.
24. Vucic EA, Thu KL, Robison K, Rybaczyk LA, Chari R, Alvarez CE, et al. Translating cancer 'omics' to improved outcomes. Genome Res 2012;22(2):188-95.
25. Sinha P, Bahadur S, Thakar A, Matta A, Macha M, Ralhan R, et al. Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. Head & Neck 2009;31(11):1423-30.
26. Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, et al. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 2006;132(11):735-43.
27. Talikka M, Sierro N, Ivanov N, Chaudhary N, Peck M, Hoeng J, et al. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol 2012;42(10):877-89.
28. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006;66(3):1371-5.
29. von Zeidler SV, Miracca E, Nagai M, Birman E. Hypermethylation of the p16 gene in normal oral mucosa of smokers. Int J Mol Med 2004;14(5):807.
30. Kulkarni V, Saranath D. Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 2004;40(2):145-53.
31. Zou H, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, et al. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14(4):830-4. Epub 2005/04/13.
32. Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, Siegmund KD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 2011;6(6):e21443. Epub 2011/07/ 07.
33. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, et al. Single-CpGresolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012;33(8):1487-93. Epub 2012/05/23.
34. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Esteller M, Lothe RA. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J Pathol 2006;210(4):441-9. Epub 2006/10/10.
35. Gilbert P.M, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest 2010;120(5):1535-50. Epub 2010/04/15.
36. Ishii M, Oyama A, Hagiwara T, Miyazaki A, Mori Y, Kiuchi Y, et al. Facilitation of H2O2-induced A172 human glioblastoma cell death by insertion of oxidative stress-sensitive TRP.M2 channels. Anticancer Res 2007;27(6B):3987-92. Epub 2008/01/30.
37. Zeng X, Sikka SC, Huang L, Sun C, Xu C, Jia D, et al. Novel role for the transient receptor potential channel TRP.M2 in prostate cancer cell proliferation. Prostate Cancer Prostatic Dis 2010;13(2):195-201. Epub 2009/12/24.
38. Rennie PS, Mawji NR, Coldman AJ, Godolphin W, Jones EC, Vielkind JR, et al. Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRP.M-2, with survival in patients with breast cancer. Cancer 1993;72(12):3648-54. Epub 1993/12/15.
39. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 2009;281(2):128-33. Epub 2008/12/30.
40. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28(35):3097-110. Epub 2009/07/15.
41. Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol 2006;208(5):662-72. Epub 2006/ 01/10.
42. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 2004;39(4):1038-47. Epub 2004/04/02.
43. Sel S, Ebert T, Ryffel GU, Drewes T. Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Cancer Lett 1996;101(2):205-10. Epub 1996/03/ 29.
44. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25(8):1091-3. Epub 2009/02/25.
45. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434(7035):843-50. Epub 2005/04/15.
46. Noguti J, CF DEM, Hossaka TA, Franco M, Oshima CT, Dedivitis RA, et al. The role of canonical WNT signaling pathway in oral carcinogenesis a comprehensive review. Anticancer Res 2012;32(3):873-8. Epub 2012/03/09.
47. Andrade Filho PA, Letra A, Cramer A, Prasad JL, Garlet GP, Vieira AR, et al. Insights from studies with oral cleft genes suggest associations between WNTpathway genes and risk of oral cancer. J Dent Res 2011;90(6):740-6. Epub 2011/03/12.
48. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol 2008;32(6):1253-61. Epub 2008/05/24.
49. Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, et al. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 2010;24(4):1035-41. Epub 2010/09/03.
50. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009;4(5):307-12. Epub 2009/07/28.
51. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/ BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007;67(11):5461-70. Epub 2007/06/05.
52. Velasco A, Pallares J, Santacana M, Gatius S, Fernandez M, Domingo M, et al. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Hum Pathol 2011;42(2):185-93. Epub 2010/11/30.
53. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004;22(22):4584-94. Epub 2004/11/16.
54. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26(22):3279-90. Epub 2007/05/15.